The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy
Open accessAbstract
We compared maternal and neonatal outcomes in diabetic pregnancies treated with either insulin glargine or neutral protamine Hagedorn (NPH) insulin. We performed a retrospective chart review of diabetic pregnant patients using the Diabetes Care Center of Wake Forest University during the years 2000 to 2005. Outcomes of interest included maternal hemoglobin A1C, average fasting and 2-hour postprandial blood sugars, mode of delivery, birth weight, 5-minute Apgar score < 7, umbilical artery pH < 7.20, incidence of neonatal hypoglycemia, and pregnancy complications. A total of 52 diabetic pregnant patients were included in this study. Twenty-seven women used insulin glargine. A total of 13 women used insulin glargine during the first trimester. Glycemic control was similar in women who used NPH insulin and insulin glargine, as determined by hemoglobin A1C levels and mean blood sugar values. There were no differences in mode of delivery, average birth weight, or neonatal outcomes. Maternal and fetal/neonatal outcomes appear similar in pregnant diabetic women who use either NPH insulin or insulin glargine in combination with a short-acting insulin analogue to achieve adequate glycemic control during pregnancy. Insulin glargine appears to be an effective insulin analogue for use in women whose pregnancies are complicated by diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303 · cited 1×
“Diabetes during pregnancy has also been shown to increase the risk of development of obesity, diabetes, and metabolic syndrome in offspring.(1,2) Maternal complications associated with diabetes in pregnancy include pregnancy-induced hypertension, preeclampsia, and worsening of chronic complications of diabetes includi…”
Reduced Hypoglycemia Risk With Insulin Glargine
Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., & Salzman, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.950 · Cited by 371
Bähr, M., Kolter, T., Seipke, G., & Eckel, J. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00903-x · Cited by 107
Ciaraldi, T. P., Carter, L., Seipke, G., Mudaliar, S. R. D., & Henry, R. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8110 · Cited by 104
Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus
Persson, B., Swahn, M.-L., Hjertberg, R., Hanson, U., Nord, E., Nordlander, E., & Hansson, L.-O. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00141-9 · Cited by 103
Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy.
Kitzmiller, J. L., Main, E. K., Ward, B., Theiss, T. S., & Peterson, D. L. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.874 · Cited by 95
Berti, L., Kellerer, M., Bossenmaier, B., Seffer, E., Seipke, G., & Häring, H.-U. (1998) · Hormone and Metabolic Research · doi:10.1055/s-2007-978849 · Cited by 93
Use of insulin glargine during pregnancy: a case-control pilot study
Price, N., Bartlett, C., & Gillmer, M. (2007) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01216.x · Cited by 93
Evaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and Mice
Stammberger, I., Bube, A., Durchfeld-Meyer, B., Donaubauer, H. H., & Troschau, G. (2002) · International Journal of Toxicology · doi:10.1080/10915810290096306 · Cited by 90 · cited 1×
“5 IU/kg of insulin glargine failed to show an increase in tumor formation after prolonged exposure.(21) Perhaps most importantly, despite widespread use in the adult diabetic population, there have been no reports of adverse effects in nonpregnant humans.”
Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro
Loukovaara, S., Immonen, I., Teramo, K. A., & Kaaja, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1193 · Cited by 80
Research works printed but not linked: 7
- [2]Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care 1998;21:B142–B149
- [9]Di Cianni G, Volpe L, Lencioni C, et al. Use of insulin glargine during the first weeks of pregnancy in five type I diabetic women. Diabetes Care 2005;28:982–983 INSULIN GLARGINE VERSUS NPH INSULIN FOR DIABETES IN PREGNANCY/SMITH ET AL 61
- [10]Holstein A, Plasche A, Egberts EH. Use of insulin glargine during embryogenesis in a pregnant woman with type I diabetes. Diabet Med 2003;20:779–780
- [11]Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a type I diabetic woman. Diabetes Care 2002;25:1095–1096
- [14]Gallen IW, Roland JM, Chirayath HH. Survey of glargine use in 115 pregnant women with type I diabetes. Diabet Med 2008;25:165–169
- [17]Kurtzhals P, Schaffer L, Sorenson A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes 2000;49: 999–1005
- [22]Lauszus FF, Klebe JG, Bek T, Flyvbjerg A. Increased serum IGF-1 during pregnancy is associated with progression of diabetic retinopathy. Diabetes 2003;52:852–856
Cited by
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
Gestational diabetes: risk factors and recent advances in its genetics and treatment
Petry, C. J. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510001741 · Cited by 180
Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis
Pollex, E. K., Moretti, M. E., Koren, G., & Feig, D. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p327 · Cited by 124
Lepercq, J. A., Lin, J., Hall, G. C., Wang, E., Dain, M., Riddle, M. C., & Home, P. (2012) · Obstetrics and Gynecology International · doi:10.1155/2012/649070 · Cited by 99
“The incidence of macrosomia [35, 39, 41, 42], LGA infants [35, 37–39], and 5-minute Apgar scores <7 [37– 39, 42] were each reported in four of the eight studies.”
BackgroundResultInfluentialSafety of insulin analogs during pregnancy: a meta-analysis
Lv, S., Wang, J., & Xu, Y. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3692-3 · Cited by 88
“3a) [16–19, 21, 22].”
Metadata
- Authors
- Smith, J., Manuck, T., White, J., & Merrill, D.
- Affiliations
- Wake Forest University Health Sciences (US)
- Atrium Health Wake Forest Baptist (US)
- ORCID
- Manuck, Tracy
- Venue
- American Journal of Perinatology
- Publisher
- Georg Thieme Verlag KG
- Published
- 2008-10-31
- Volume
- 26
- Issue
- 01
- Pages
- 057-062
- ISSN
- 0735-1631 (ISSN-L)
- 1098-8785
- OpenAlex
- W1970481694
- Cited by
- 22
- References
- 20
- Citations by year
- 2022: 1 · 2021: 1 · 2019: 2 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 3
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- American Journal of Perinatology (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- insulin glargine, neutral protamine Hagedorn insulin, diabetes in pregnancy, glycemic control, HbA1c, neonatal outcomes, neonatal hypoglycemia, birth weight, mode of delivery, insulin analogues, short-acting insulin, pregnancy complications
- MeSH terms
- Insulin Glargine, Adult, Apgar Score, Birth Weight, Blood Glucose, Carbon Dioxide, Eating, Fasting, Female, Gestational Age, Glycated Hemoglobin, Humans, Hydrogen-Ion Concentration, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Insulin, Insulin, Isophane, Oxygen, Pregnancy, Pregnancy Complications, Pregnancy in Diabetics, Pregnancy Outcome, Retrospective Studies, Umbilical Arteries, Diabetes, Gestational, Delivery, Obstetric, Insulin, Long-Acting, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy. https://app.cochat.ai/papers/10.1055/s-0028-1095181
- The paper
- Smith, J., Manuck, T., White, J., & Merrill, D. (2009). Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy. American Journal of Perinatology. https://doi.org/10.1055/s-0028-1095181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.